# Elanco Animal Health (ELAN) — News

ELAN · NYSE · Stock

Canonical page: https://www.lighthorse.io/tickers/elan/news

## Recent headlines

- [Biocon's Shaw: Biosimilars a very attractive segment](https://www.ainvest.com/news/biocon-shaw-biosimilars-attractive-segment-2610) — AInvest Wire, Oct 13, 2026
  Biocon, India’s largest biopharmaceutical company, has positioned itself as a key player in the global biosimilars market, with its chairman and managing director, Kiran Mazumdar-Shaw, emphasizing the segment’s growing potential. The company recently received approval for its Glargine biosimilar in…
- [Neurizon Therapeutics - Sergio Duchini transitions to non-executive chairman](https://www.ainvest.com/news/neurizon-therapeutics-sergio-duchini-transitions-executive-chairman-2610) — AInvest Wire, Sep 30, 2026
  Neurizon Therapeutics Limited (ASX: NUZ) has announced that Sergio Duchini has transitioned from the role of Chief Executive Officer to Non-Executive Chairman of the Board , effective September 7, 2026. This change follows the appointment of Dr. Michael Thurn as the company’s new Chief Executive…
- [Neurizon Therapeutics Ltd-Elanco representative appointed as Neurizon board observer](https://www.ainvest.com/news/neurizon-therapeutics-elanco-representative-appointed-neurizon-board-observer-2608) — AInvest Wire, Aug 12, 2026
  Neurizon Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) has announced appointment of Ms Justine Conway as a Board Observer, effective November 26, 2025. Ms Conway currently serves as Global Head of Business Development at Elanco Animal Health (NYSE: ELAN) and will represent Elanco in…
- [Elanco Animal Health Inc outlook Q3 adj EPS $0.19 - $0.22](https://www.ainvest.com/news/elanco-animal-health-outlook-q3-eps-0-19-0-22-2608) — AInvest Wire, Aug 5, 2026
- [Elanco Animal Health shares up 6.5% premarket after Q2 results beat](https://www.ainvest.com/news/elanco-animal-health-shares-6-5-premarket-q2-results-beat-2608) — AInvest Wire, Aug 5, 2026
  Elanco Animal Health (NYSE: ELAN) shares rose 6.5% in premarket trading following the release of its second-quarter financial results, which exceeded expectations. The company reported stronger-than-anticipated earnings, driven by solid performance across its product portfolio and operational…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).